Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys

Background: Chronic treatment with l-3,4-dihydroxyphenylalanine (l-dopa) is often associated with motor side effects in PD patients. The search for new therapeutic approaches has led to study the role of other neuromodulators including adenosine. Among the four adenosine receptors characterized so far, the A2A subtype is distinctively present on striatopallidal output neurons containing enkephalin and mainly bearing dopamine (DA) D2 receptors (indirect pathway). Studies in DA-denervated rats suggest that blockade of adenosine A2A receptors might be used in PD. Objective: To evaluate the antiparkinsonian effect of a new selective adenosine A2A receptor antagonist, KW-6002, in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated monkeys. Methods: In the present study, we used six MPTP-exposed cynomolgus monkeys already primed and exhibiting l-dopa–induced dyskinesias to evaluate both the antiparkinsonian and dyskinetic effect upon challenge with two oral doses (60 and 90 mg/kg) of KW-6002 administered alone or in combination with l-dopa/benserazide (50/12.5 mg). Results: KW-6002 administered alone produced a dose-dependent antiparkinsonian response that reached the level of efficacy of l-dopa/benserazide but was less likely to reproduce dyskinesias in these animals. When co-administered, KW-6002 potentiated the effects of l-dopa/benserazide on motor activity (up to 30%) without affecting the dyskinetic response. Conclusion: Adenosine A2A receptor antagonists have antiparkinsonian effects of their own with a reduced propensity to elicit dyskinesias. They might therefore be useful agents in the treatment of PD.

[1]  P. Jenner,et al.  Adenosine A2A Antagonist: A novel antiparkinsonian agent that does not provoke dyskinesia in Parkinsonian monkeys , 1998, Annals of neurology.

[2]  P. Bédard,et al.  Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: An acute study in parkinsonian levodopa-primed monkeys , 1997, Neurology.

[3]  E. Ongini,et al.  Adenosine A2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats. , 1997, European journal of pharmacology.

[4]  B. Fredholm,et al.  Pharmacology of adenosine A2A receptors. , 1996, Trends in pharmacological sciences.

[5]  G. Chiara,et al.  Blockade of A2a Adenosine Receptors Positively Modulates Turning Behaviour and c‐Fos Expression Induced by D1 Agonists in Dopamine‐denervated Rats , 1996, The European journal of neuroscience.

[6]  T. Shindou,et al.  The role of adenosine A2a receptors in regulating GABAergic synaptic transmission in striatal medium spiny neurons. , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[7]  J. Gusella,et al.  Characterization and Expression of the Human A2a Adenosine Receptor Gene , 1996, Journal of neurochemistry.

[8]  J. Fink,et al.  Adenosine antagonists potentiate D2 dopamine-dependent activation of Fos in the striatopallidal pathway , 1995, Neuroscience.

[9]  S G Holtzman,et al.  Does adenosine receptor blockade mediate caffeine-induced rotational behavior? , 1995, The Journal of pharmacology and experimental therapeutics.

[10]  H. Kase,et al.  Inhibition by KF17837 of adenosine A2A receptor‐mediated modulation of striatal GABA and ACh release , 1994, British journal of pharmacology.

[11]  G Burnstock,et al.  Nomenclature and Classification of Purinoceptors* , 2005 .

[12]  S. Shiozaki,et al.  KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity. , 1994, European journal of pharmacology.

[13]  S. Augood,et al.  Adenosine A2a receptor mRNA is expressed by enkephalin cells but not by somatostatin cells in rat striatum: a co-expression study. , 1994, Brain research. Molecular brain research.

[14]  G. Di Chiara,et al.  Adenosine A2 receptors interact negatively with dopamine D1 and D2 receptors in unilaterally 6-hydroxydopamine-lesioned rats. , 1994, European journal of pharmacology.

[15]  G. Wooten,et al.  Differential localization of A2a adenosine receptor mRNA with D1 and D2 dopamine receptor mRNA in striatal output pathways following a selective lesion of striatonigral neurons , 1993, Brain Research.

[16]  J. Kebabian,et al.  Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- exposed monkeys. , 1993, The Journal of pharmacology and experimental therapeutics.

[17]  B. Parsons,et al.  Adenosine receptor antagonists potentiate dopamine receptor agonist-induced rotational behavior in 6-hydroxydopamine-lesioned rats , 1993, Brain Research.

[18]  K. Fuxe,et al.  Dopamine denervation leads to an increase in the intramembrane interaction between adenosine A2 and dopamine D2 receptors in the neostriatum , 1992, Brain Research.

[19]  E. M. Adler,et al.  Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum. , 1992, Brain research. Molecular brain research.

[20]  J. Palacios,et al.  Adenosine A2 receptors: Selective localization in the human basal ganglia and alterations with disease , 1991, Neuroscience.

[21]  K. Jacobson,et al.  Behavioral effects of A1- and A2-selective adenosine agonists and antagonists: evidence for synergism and antagonism. , 1991, The Journal of pharmacology and experimental therapeutics.

[22]  S. Schiffmann,et al.  Distribution of adenosine A2 receptor mRNA in the human brain , 1991, Neuroscience Letters.

[23]  S. Schiffmann,et al.  Striatal Restricted Adenosine A2 Receptor (RDC8) Is Expressed by Enkephalin but Not by Substance P Neurons: An In Situ Hybridization Histochemistry Study , 1991, Journal of neurochemistry.

[24]  B B Fredholm,et al.  Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[25]  U. Ungerstedt,et al.  Postsynaptic dopamine/adenosine interaction: I. Adenosine analogues inhibit dopamine D2-mediated behaviour in short-term reserpinized mice. , 1991, European journal of pharmacology.

[26]  M. Reddington,et al.  Both A1 and A2a Purine Receptors Regulate Striatal Acetylcholine Release , 1990, Journal of neurochemistry.

[27]  S. Schiffmann,et al.  A cloned G protein-coupled protein with a distribution restricted to striatal medium-sized neurons. Possible relationship with D1 dopamine receptor , 1990, Brain Research.

[28]  K. Jacobson,et al.  Characterization of the locomotor depression produced by an A2‐selective adenosine agonist , 1990, FEBS letters.

[29]  M. Williams,et al.  Direct autoradiographic localization of adenosine A2 receptors in the rat brain using the A2-selective agonist, [3H]CGS 21680. , 1989, European journal of pharmacology.

[30]  J. Carney,et al.  Effects of selected analogs of adenosine on schedule-controlled behavior in rats , 1986, Neuropharmacology.

[31]  G. Lu,et al.  Characterization of the A2 adenosine receptor labeled by [3H]NECA in rat striatal membranes. , 1986, Molecular pharmacology.

[32]  A. K. Aggarwal,et al.  Dissociation of the locomotor and hypotensive effects of adenosine analogues in the rat , 1984, Neuroscience Letters.

[33]  J. Phillis,et al.  Central effects of adenosine analogs on locomotor activity in mice and antagonism of caffeine , 1983, Brain Research.

[34]  S H Snyder,et al.  Adenosine receptors and behavioral actions of methylxanthines. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Margarete Müller,et al.  ADENOSINE REGULATES VIA TWO DIFFERENT TYPES OF RECEPTORS, THE ACCUMULATION OF CYCLIC AMP IN CULTURED BRAIN CELLS , 1979, Journal of neurochemistry.

[36]  J. Kebabian,et al.  Multiple receptors for dopamine , 1979, Nature.

[37]  G. Stiles,et al.  Adenosine receptor subtypes: characterization and therapeutic regulation. , 1995, Annual review of pharmacology and toxicology.